20-F: Bioceres Faces Going Concern Doubt Amidst Revenue Plunge

Bioceres Crop Solutions Corp. reported a significant net loss and revenue decline for fiscal year 2025, triggering a 'going concern' warning and reclassifying substantial debt as current due to covenant breaches.

Summary

• Total revenue decreased by 28% to US$335.1 million for the year ended June 30, 2025, down from US$464.8 million in the prior year.
• The company reported an operating loss of US$2.2 million for fiscal year 2025, a sharp decline from an operating profit of US$45.9 million in fiscal year 2024.
• Net loss for the year was US$58.8 million, compared to a net profit of US$7.3 million in the previous fiscal year.
• Adjusted EBITDA decreased by 65.2% to US$28.3 million in fiscal year 2025 from US$81.4 million in fiscal year 2024.
• US$102.3 million of the company's Secured Notes were reclassified as a current liability due to a breach of financial covenants, indicating an inability to defer settlement for at least twelve months.
• The seed business underwent a major restructuring, discontinuing direct sales of HB4 wheat and soybean seeds and transitioning to a licensing-based model.
• Argentina, a key market, experienced severe challenges due to extraordinary prior-year sales leading to inventory accumulation, deteriorating on-farm economics, and constrained financing availability.
• Research and development expenses decreased to US$14.9 million, reflecting a refocusing of resources towards nearer-term profitability opportunities.
• Selling, general and administrative expenses decreased slightly to US$123.1 million, but included a US$6.4 million increase in impairment of receivables and US$3.5 million in workforce streamlining costs.
• A transaction involving non-core soybean traits and intellectual property assets resulted in a US$7.5 million gain from the exchange of intangible assets.

Sentiment

Score: 2

Explanation: The company reported a significant decline in revenue and profitability, moving from profit to substantial loss. A 'going concern' warning was issued by auditors, and a large portion of debt was reclassified as current due to covenant breaches. While strategic shifts and R&D efforts are noted, the immediate financial health and liquidity concerns are severe.

Positives

• The company's R&D engine is robust, focused on creating biological products that improve crop performance and environmental sustainability, with over 51 active projects.
• Strategic partnerships with global agriculture leaders like Syngenta and Corteva enhance market access and product development.
• The transition to a licensing-based model for HB4 technology aims to broaden adoption and reduce fixed costs, aligning with core competencies.
• A strategic agreement with Grupo Don Mario (GDM) expands the use of Verdeca's patented platform for new soybean varieties.
• An agreement with Colorado Wheat Research Foundation (CWRF) grants exclusive rights to manage HB4 trait access in wheat within the United States.
• The company maintains a strong intellectual property portfolio with over 750 patents and patent applications, and over 1,394 trademarks globally.
• Bioceres has made significant investments in manufacturing capacity, including a new high-tech adjuvant facility in Brazil and expanded biologicals production in Argentina.

Negatives

• The company's financial statements for the year ended June 30, 2025, state that there is substantial doubt about its ability to continue as a going concern.
• Total revenue decreased by 28% to US$335.1 million, driven by severe challenges in the Argentine market and a strategic shift in the HB4 business model.
• Operating profit declined significantly from US$45.9 million in 2024 to an operating loss of US$2.2 million in 2025.
• Net profit turned into a substantial net loss of US$58.8 million in 2025, compared to a US$7.3 million profit in 2024.
• Adjusted EBITDA saw a sharp decrease of 65.2% to US$28.3 million.
• A breach of financial covenants on the Secured Notes led to US$102.3 million being reclassified as a current liability, increasing short-term debt obligations.
• The company currently does not have a permanent Chief Financial Officer, which may hinder remediation efforts and timely SEC filings.
• Workforce streamlining costs of US$3.5 million and a US$6.4 million increase in impairment of receivables negatively impacted SG&A expenses.
• The company's ability to generate cash flow over the next twelve months depends on securing additional financing or successfully implementing restructuring initiatives, which cannot be guaranteed.
• Bioceres S.A., a former ultimate controlling parent, defaulted on a portion of its financial debt, creating uncertainty with local banks in Argentina and suspending access to credit lines.

Risks

• Insufficient cash flow to service indebtedness, including recently amended Convertible Notes and Non-Convertible Notes, raising substantial doubt about the ability to continue as a going concern.
• Inability to obtain additional capital on acceptable terms, limiting business plan execution and operational expansion.
• Failure to successfully develop marketable or commercial technologies, leading to no or insufficient revenue generation from products in development.
• Difficulties or delays in obtaining necessary regulatory approvals for products, affecting market access and sales.
• Dependence of the HB4 seed business on a licensed technology subject to termination provisions and the successful transition to a licensing-based model.
• Limited number of prospective collaborators in the highly consolidated crop productivity market.
• Joint venture agreements or partnerships may not be successful, or collaborators may fail to perform contractual obligations, leading to disputes and reduced revenues.
• Difficulties in collecting payments or royalties from licensees and end-users, impacting business and financial results.
• Challenges in implementing inorganic growth strategy and integrating acquired businesses, potentially disrupting operations and affecting debt servicing ability.
• Indebtedness could adversely affect financial condition, limiting access to additional financing and increasing vulnerability to adverse economic conditions.
• Breach of financial covenants could accelerate repayment obligations and materially adversely affect liquidity and ability to fund operations.
• Requirements of being a public company may strain resources and distract management.
• Dependence on key personnel and research collaborators, with potential adverse effects if unable to attract and retain qualified staff; currently lacks a Chief Financial Officer.
• Inability to prevent competitors from benefiting from the expertise of former employees due to lack of non-compete agreements with all staff.
• Adverse changes in global economic conditions, including armed conflicts (Israel/Gaza, Ukraine) and trade barriers, may negatively affect the industry and business.
• The seasonal nature of crops and uncontrollable factors (weather, natural disasters) could cause significant fluctuations in sales and operating results.
• Consumer and government resistance to genetically modified (GM) crops may negatively impact public image and reduce demand for products.
• Intense competition in crop productivity products requiring continuous technological development.
• Changes in laws and regulations may materially increase operating costs, decrease revenue, and disrupt business.
• Price increases and shortages of raw materials could adversely affect results of operations.
• Exposure to market risks from commodity price volatility, impacting grower purchasing decisions.
• Potential for substantial damages from uninsured product liability claims, including those related to cross-pollination or cross-contamination.
• Operations are subject to health and environmental risks from toxic materials, potentially leading to fines, liability, and reputational harm.
• Development and commercialization of products may incur scrutiny under the Convention on Biological Diversity Treaty.
• Failure to accurately forecast and/or manage biological inventory could result in unexpected shortfalls or surpluses.
• Reliance on third parties to grow seeds with HB4 Technology, with limited control over their commercial strategies, production quality, and market performance.
• Disruption to IT and operating systems could adversely affect reputation and business.
• Computer system failures, cyber-attacks, or cybersecurity deficiencies could adversely affect business and operations.
• Labor union disputes may arise, consuming management time and distracting from business.
• Non-compliance with anti-corruption and anti-money laundering laws can subject the company to criminal and civil liability.
• Economic substance legislation of the Cayman Islands may adversely impact the company or its operations.
• Potential for taxation in the Cayman Islands, negatively affecting results.
• Adverse economic or political conditions in Latin America, including inflation, government controls, and economic uncertainty, may impact business.
• Significant government influence over Latin American economies could negatively impact operational flexibility and profitability.
• Fluctuations in currency exchange rates may affect financial results and cash flows, particularly in Argentina and Brazil.
• Application of inflationary adjustments and tax indexation procedures in Argentine subsidiaries could adversely affect financial statements.
• Limited access of Argentine government and private sector to international capital markets could restrict the company's ability to raise funds.
• A decline in global prices of Latin America's main commodity exports could adversely affect regional economic growth and the company's revenue.
• Potential for special protections for employees in the private sector in Argentina, increasing labor costs.
• Disposition or sale of ordinary shares may be subject to taxation in Argentina.
• Payment of In-Kind Consideration under the Rizobacter Call Option may be subject to taxation in Argentina.
• Argentine exchange controls and restrictions limit access to the FX Market for payments and distributions from Argentine subsidiaries.
• Mandatory repatriation of export receivables may limit financial flexibility and expose the company to currency risks.
• Changes in Argentine tax laws may adversely affect results of operations, financial condition, and cash flows.
• Share repurchase program may reduce liquidity.
• Inability to comply with Nasdaq listing standards could result in delisting.
• Sales of a substantial number of ordinary shares by shareholders could adversely affect market price.
• Conversion of Convertible Secured Guaranteed Notes would increase ordinary shares and result in dilution to shareholders.
• Reliance on home country corporate governance practices as a foreign private issuer may afford less protection to shareholders.
• Fluctuation in the price of securities, leading to potential loss of investment.
• Cessation of research or reports by securities analysts, or adverse changes in recommendations, could cause share price decline.
• Difficulties for public shareholders in protecting interests through U.S. Federal courts due to Cayman Islands incorporation.
• Historically, no cash dividends paid on ordinary shares.
• Issuance of additional securities in the future may result in dilution to shareholders.

Future Outlook

The company is actively pursuing alternatives to address its financial situation, including optimizing working capital, realigning cost structure, and engaging with local Argentine banks to refinance current debt. The outlook for upcoming agricultural campaigns in Argentina remains positive, based on expectations of a more favorable macroeconomic environment and normalized climatic conditions. However, the generation of cash flows over the next twelve months depends on the success of these initiatives, which cannot be guaranteed.

Management Comments

• We faced severe challenges in Argentina, one of our key markets, during the year ended June 30, 2025, driven by a combination of factors: (i) extraordinary prior-year sales linked to local currency devaluation, which led distribution channels to accumulate inventories beyond short-term needs; (ii) deteriorating on-farm economics; and (iii) constrained financing availability across the agricultural sector.
• The reduction in demand, combined with a well-supplied ag-inputs market resulting from aggressive purchasing in prior years, has led to increased price pressure and lower adoption of high-value technologies like ours.
• Despite the adverse impact of financial difficulties faced by agricultural producers, we were able to maintain our market share in key product families and the outlook for upcoming campaigns remains positive in Argentina. This optimism is grounded in expectations of a more favorable macroeconomic environment in the country and the normalization of climatic conditions affecting the agricultural sector.

Industry Context

The agricultural industry faces a major global challenge to meet increasing food demand sustainably, requiring innovation in climate-adaptive biotechnology and biological products. The market for biologicals is the fastest-growing segment in agricultural inputs, driven by regulatory policies encouraging bio-based products, the need for improved soil health, pest resistance, and climate change impacts. Bioceres' product portfolio, including HB4 technology and biological solutions, is positioned to address these sustainability-driven trends, despite intense competition from large agricultural companies and specialized biopesticide businesses. The global seed market and genetically modified seed market are projected for significant growth, underscoring the increasing importance of agricultural biotechnology.

Comparison to Industry Standards

• Bioceres is a pioneer in the agriculture biotechnology industry as the first and only company in the world to develop a drought-tolerant technology for soybean and wheat cropping systems, distinguishing it from competitors like Bayer and Corteva who primarily focus on herbicide tolerance and insect resistance.
• The company is the first non-governmental Latin America-based entity with an approved biotech event in a major global crop.
• HB4 drought-tolerant wheat is the only genetically modified wheat approved anywhere (Argentina, Brazil, Paraguay, United States) and on a commercial path to market globally, representing a major milestone in wheat's global value chain, where wheat has historically been an orphan crop in biotechnology.
• Rizobacter, a subsidiary, holds an estimated 20% global market share in soybean inoculants, positioning it as a global leader ahead of key competitors like Novozymes and Becker Underwood.
• In the Argentine phosphorus fertilizer market, Rizobacter leads with a specialty micro-beaded product that requires substantially lower doses than competitors' products, offering a competitive advantage in storage and logistics over companies like Recuperar, FYO, and Red Surcos.
• The global biocontrol market is estimated at US$9 billion for 2024 and projected to reach over US$15 billion by 2029 (CAGR of 11%), indicating Bioceres' expanded portfolio in this area through the Pro Farm Merger aligns with a high-growth segment.
• The biostimulants market, valued at US$3.5 billion in 2024, is projected to grow at an 11.2% CAGR to US$5.9 billion by 2029, showing Bioceres' focus on this area is in line with rapid industry expansion driven by climate change and soil degradation.

Management Changes

Corporate Governance

Legal Proceedings

• An injunction related to a disputed share transfer in 1995 affects 29% of the Rizobacter shares held by the company (44% of Rizobacter's total share capital). If decided unfavorably, the company may be required to surrender part of its interest in Rizobacter, reducing its equity stake. The injunction also requires 30% of dividends on affected shares to be paid into an escrow account. A contingent purchase price of US$17.3 million may be payable if the court rules against the free transferability of shares.

Related Party Transactions

• Bioceres Group Limited, the former ultimate controlling parent, owns approximately 10% of the company's ordinary shares as of October 28, 2025, following a reduction in beneficial ownership due to private transactions.
• Bioceres LLC, an affiliate of Bioceres Group Limited, holds shared voting power over 3,076,079 ordinary shares through the Rizobacter Shareholders Agreement.
• Moolec Science SA, now the parent of Bioceres Group Limited, received US$6.6 million in convertible notes from the company in September 2024 in exchange for HB4 soy supply.
• INDEAR (an affiliate) leases a field station from Rizobacter Argentina S.A. for an annual amount of US$40,000, with INDEAR indemnifying Rizobacter for liabilities.
• Synertech Industrias S.A. (a joint venture) entered into a deposit and storage services agreement with Rizobacter, paying US$6,500 monthly.
• BCS Holding Inc. granted Trigall Genetics S.A. (a joint venture) an exclusive sub-license of HB4 technology in wheat for research and commercial use in Argentina, Paraguay, Brazil, and Uruguay.
• Trigall Genetics S.A. pays BCS Holding Inc. and Florimond Desprez Veuve & Fils SAS for R&D services, with the budget approved annually by Trigall's board.
• Espartina S.A., controlled by Marcelo Carrique (former President of Rizobacter), performs planting and harvesting services for Rizobacter, with profits distributed according to contributions.
• Funds affiliated with Mr. Ari Freisinger, a former director, purchased US$9 million Secured Convertible Guaranteed Notes.

Stakeholder Impact

• Shareholders face significant dilution risk from potential future equity offerings and the conversion of Convertible Secured Guaranteed Notes.
• Shareholders may lose all or part of their investment if the company is unable to continue as a going concern and is required to liquidate assets.
• Creditors face increased risk due to the reclassification of US$102.3 million in Secured Notes as current liabilities and the company's breach of financial covenants.
• Employees are impacted by workforce streamlining costs of US$3.5 million and potential instability due to management changes and the lack of a permanent CFO.
• Customers may experience changes in product availability and commercialization strategies due to the restructuring of the HB4 seed business and the shift to a licensing model.
• Suppliers and partners may face uncertainty regarding the company's financial stability and ability to meet contractual obligations, especially in Argentina's challenging market.

Next Steps

• Actively pursue several alternatives to address the current financial situation, including optimizing working capital and realigning cost structure.
• Engage with local Argentine banks to refinance current debt and restore confidence in the business.
• Continue discussions regarding a new long-term facility or capital raise.
• Continue advancing agricultural biotechnology and biological products, focusing on microbial technologies and seed traits.
• Optimize manufacturing capacity, leveraging recent investments in Brazil and Argentina.
• Commercialize HB4 traits through licensing partnerships to expand product portfolio and increase adoption.
• Strengthen international expansion, particularly for biologicals, adjuvants, and nutrition products.
• Pursue strategic collaborations and selective acquisitions that are capital-efficient and synergistic with the existing portfolio.
• Continue the search for a new Chief Financial Officer.

Key Dates

Recommendation

The company's financial results for fiscal year 2025 are severely negative, with a substantial net loss and a significant drop in Adjusted EBITDA. The auditor's 'going concern' warning, coupled with the breach of financial covenants leading to a large reclassification of debt as current, indicates severe liquidity and solvency issues. While strategic shifts and R&D efforts are underway, the immediate financial distress and the high level of uncertainty surrounding future financing and operational stability make the stock a high-risk investment with significant downside potential. A seasoned investor would likely divest to avoid further capital erosion.

Keywords

Crop Solutions, Agricultural Biotechnology, SEC Filing, Financial Performance, Going Concern, Debt Covenants, HB4 Technology, Licensing Model, Argentina Market, Biocontrol, Crop Nutrition, R&D, SEC 20-F, Bioceres, BIOX, Nasdaq